Inflammation-Induced CNS Glutamate Changes in Depression
Overview
- Phase
- Phase 4
- Intervention
- Infliximab
- Conditions
- Depression
- Sponsor
- Emory University
- Enrollment
- 22
- Locations
- 1
- Primary Endpoint
- Central Nervous System (CNS) Glutamate
- Status
- Terminated
- Last Updated
- 2 years ago
Overview
Brief Summary
Increased inflammation has been implicated in the pathophysiology of a number of neuropsychiatric illnesses including mood disorders, which affect almost 30 million adults in the United States alone. One mechanism by which inflammation may alter behavior is through increasing brain glutamate, a neurotransmitter that in excess has been implicated in neuronal toxicity and resistance to conventional antidepressant therapy. The goal of the proposed research is to test the hypothesis that inflammation alters behavior through increasing glutamate in specific brain regions, ultimately leading to behavioral changes.
The proposed research is designed to determine the cause and effect relationship between inflammation and CNS glutamate as well as the relationship between CNS glutamate and specific symptoms. To accomplish these aims, investigators will administer a single infusion of either the tumor necrosis factor (TNF) antagonist infliximab or placebo (n=30 per group) to patients with high inflammation (CRP>3mg/L). A CRP>3mg/L was chosen because it is considered high inflammation according to guidelines by the American Heart Association. Moreover, a CRP>3mg/L is associated with significantly increased basal ganglia glutamate and with a clinical response to infliximab. Inflammatory biomarkers, basal ganglia glutamate as measured by MRS, and motivation and psychomotor activity will be assessed at baseline and days 1 and 3 and weeks 1 and 2 following infliximab or placebo administration.
Detailed Description
This study aims to test the hypothesis that increased inflammation causes increased basal ganglia glutamate and consequently anhedonia and psychomotor retardation in patients with major depressive disorder (MDD). Excessive inflammation and glutamate excitotoxicity are two pathways that have received increasing attention regarding the pathophysiology of neuropsychiatric disease including mood disorders. Patients with depression exhibit increased peripheral and central nervous system (CNS) markers of inflammation as well as altered CNS glutamate as measured by magnetic resonance spectroscopy (MRS). In addition, drugs that block either inflammation or glutamate signaling can reverse depressive symptoms, especially in depressed patients with treatment resistance. Inflammatory cytokines are known to inhibit glutamate reuptake and increase glutamate release from astrocytes, and glutamate antagonists have been shown to block inflammation-induced depressive-like behavior in mice. Moreover, using MRS, data has shown that administration of the inflammatory cytokine interferon (IFN)-alpha significantly increases glutamate in the basal ganglia in association with IFN-alpha-induced anhedonia and psychomotor slowing. In addition, increased inflammation as reflected by peripheral blood C-reactive protein (CRP) is correlated with increased basal ganglia glutamate in association with decreased motivation and psychomotor speed in patients with MDD. Nevertheless, the data to date has been correlational, and whether increased inflammation causes increased glutamate in the basal ganglia, which in turn contributes to behavioral changes in patients with depression has not been established. To test this hypothesis, investigators plan to determine the cause and effect relationship between increased inflammation and increased CNS glutamate by blocking inflammation in depressed patients with high inflammation (CRP\>3mg/L) using the highly specific tumor necrosis factor (TNF) antagonist infliximab (n=30) versus placebo (n=30). In addition, the study team will examine whether changes in basal ganglia glutamate are linked to changes in behaviors related to the basal ganglia including anhedonia and psychomotor retardation.
Investigators
Andrew H Miller
Professor
Emory University
Eligibility Criteria
Inclusion Criteria
- •Willing and able to give written informed consent
- •Primary diagnosis of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) MDD, current, or Bipolar, depressed type as diagnosed by the SCID-V
- •Score of ≥14 on the Quick Inventory of Depressive Symptomatology (QIDS-SR-16) or score ≥ 15 on the Patient Health Questionnaire 9 item (PHQ-9)
- •Absence of significant suicidal ideation defined using the Columbia Suicide Severity Rating Scale - Screen Version (CSSRS)
- •Off all antidepressant or other psychotropic therapy (e.g. mood stabilizers, antipsychotics, anxiolytics, and sedative hypnotics) for at least 4 weeks prior to the baseline visit (8 weeks for fluoxetine). No patients will be removed from their psychotropic medications for the sole purpose of participating in the study.
Exclusion Criteria
- •Autoimmune disorder (as confirmed by laboratory testing)
- •History of tuberculosis (by history or as discovered by chest X-ray, skin testing or blood testing) or high risk of tuberculosis exposure
- •Hepatitis B or C infection or human immunodeficiency virus infection (as established by laboratory testing)
- •History of fungal infection
- •History of recurrent viral or bacterial infections
- •History of any type of cancer
- •Unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination and laboratory testing)
- •History of any (non-mood-related) psychotic disorder; active psychotic symptoms of any type; antisocial personality disorder as determined by a clinician; substance abuse/dependence within 6 months of study entry (as determined by SCID)
- •Active suicidal plan as determined by a score \>3 on item #3 on the Hamilton Depression Rating Scale (HAM-D)
- •Active eating disorder
Arms & Interventions
Infliximab
Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
Intervention: Infliximab
Placebo
Participants will be randomized to receive one intravenous (IV) infusion of placebo.
Intervention: Placebo
Outcomes
Primary Outcomes
Central Nervous System (CNS) Glutamate
Time Frame: Baseline, Day 3, Week 2
Left basal ganglia glutamate was measured by magnetic resonance spectroscopy (MRS). Left basal ganglia glutamate tends to be increased during inflammation and is also associated with an increase in depressive symptoms.
Secondary Outcomes
- Snaith-Hamilton Pleasure Scale - Clinician Administered (SHAPS-C) Score(Baseline, Day 3, Week 2)
- Digit Symbol Substitution Task (DSST) Score(Baseline, Day 3, Week 2)
- Plasma Concentrations of Tumor Necrosis Factor Alpha (TNF-α)(Baseline, Day 3, Week 2)
- Mood and Pleasure Scale - Self Report (MAP-SR) Score(Baseline, Day 3, Week 2)
- Finger Tapping Task (FTT) Score(Baseline, Day 3, Week 2)
- Trails Making Test A (TMT-A) Score(Baseline, Day 3, Week 2)
- Multidimensional Fatigue Inventory (MFI) Score(Baseline, Day 3, Week 2)
- Inventory of Depressive Symptoms-Clinician Rating (IDS-SR) Score(Baseline, Day 3, Week 2)
- Plasma Concentrations of High-sensitivity C-reactive Protein (Hs-CRP)(Baseline, Day 3, Week 2)
- Plasma Concentrations of Tumor Necrosis Factor (TNF) Receptor 2 (TNFR2)(Baseline, Day 3, Week 2)
- Plasma Concentrations of Soluble IL-6 Receptor (sIL-6R)(Baseline, Day 3, Week 2)
- Plasma Concentrations of Interleukin-1 Receptor Antagonist (IL-1Ra)(Baseline, Day 3, Week 2)
- Plasma Concentrations of IL-6(Baseline, Day 3, Week 2)